使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主
Operator
Operator
Good morning, ladies and gentlemen, and welcome to the Baxter International Fourth Quarter 2019 Earnings Conference Call. (Operator Instructions) As a reminder, this call is being recorded by Baxter and is copyrighted material. It cannot be recorded or rebroadcasted without Baxter's permission. If you have any objections, please disconnect at this time.
各位女士、先生,早安,歡迎參加百特國際(Baxter International)2019 年第四季財報電話會議。(接線員指示)提醒各位,本通話由百特錄音並受著作權保護。未經百特許可,不得錄音或轉播。如有任何異議,請立即中斷連線。
I would now like to turn the call over to Ms. Clare Trachtman, Vice President, Investor Relations at Baxter International. Ms. Trachtman, you may begin.
現在我想把電話交給百特國際投資人關係副總裁 Clare Trachtman 女士。Trachtman 女士,請開始。
Clare Trachtman - VP of IR
Clare Trachtman - VP of IR
Thanks, Catherine. Good morning, and welcome to our fourth quarter 2019 earnings conference call. Joining me today are Joe Almeida, Baxter's Chairman and Chief Executive Officer; and Jay Saccaro, Baxter's Chief Financial Officer.
謝謝你,Catherine。各位早安,歡迎參加我們 2019 年第四季財報電話會議。今天與我一同出席的有百特董事長兼執行長 Joe Almeida,以及百特財務長 Jay Saccaro。
On the call this morning, we will be discussing Baxter's fourth quarter and full year 2019 financial results as well as growth comparisons to restated historical financial results as disclosed in today's comprehensive 10-K filing. We will also provide our financial outlook for the first quarter of 2020. A supplemental presentation to complement this morning's discussion can be accessed on our website. This presentation, including related non-GAAP reconciliations, can be accessed on Baxter's external website in the Investors section under Events & News.
今天上午的電話會議中,我們將討論百特 2019 年第四季與全年財務結果,以及與今日完整 10-K 申報中所揭露之重編歷史財務結果的成長比較。我們也將提供 2020 年第一季的財務展望。可於我們網站取得補充簡報,以配合今天上午的討論。該簡報(含相關非 GAAP 調節表)可於百特對外網站「投資人」專區的「活動與新聞」項下取得。
With that, let me start our prepared remarks by reminding everyone that this presentation, including comments regarding our financial outlook, new product development, business development and regulatory matters, contain forward-looking statements that involve risks and uncertainties. And of course, our actual results could differ materially from our current expectations. Please refer to today's press release and our SEC filings for more detail concerning factors that could cause actual results to differ materially.
在此,我先以提醒各位作為我們事先準備講稿的開場:本簡報(包含關於我們財務展望、新產品開發、業務發展及法規事項的評論)含有涉及風險與不確定性的前瞻性陳述。當然,我們的實際結果可能與目前預期有重大差異。有關可能導致實際結果與預期出現重大差異的因素,請參閱今日新聞稿及我們向 SEC 提交的文件以取得更多細節。
In addition, on today's call, non-GAAP financial measures will be used to help investors understand Baxter's ongoing business performance. A reconciliation of the non-GAAP financial measures being discussed today to the comparable U.S. GAAP financial measures is included in our earnings release and available on our website. On the call this morning, we will be discussing operational sales growth, which for historical periods, adjust for the impact of foreign exchange and generic competition for cyclophosphamide in the U.S. Operational sales growth guidance for 2020 adjusts for the impact of foreign exchange and the acquisition of Seprafilm, which closed on February 14 of this year.
此外,在今天的電話會議中,我們將使用非 GAAP 財務衡量指標,以協助投資人了解百特持續性業務表現。今日所討論之非 GAAP 財務衡量指標與可比較之美國 GAAP 財務衡量指標的調節表,已納入我們的財報新聞稿並可於網站取得。今天上午的電話會議中,我們將討論營運銷售成長;就歷史期間而言,該指標已調整外匯影響,以及美國市場環磷醯胺(cyclophosphamide)之學名藥競爭影響。2020 年營運銷售成長指引則調整外匯影響及 Seprafilm 的收購影響(該交易已於今年 2 月 14 日完成交割)。
Now I'd like to turn the call over to Joe.
現在我想把電話交給 Joe。
José E. Almeida - Chairman, President & CEO
José E. Almeida - Chairman, President & CEO
Good morning, and thank you for joining us. Before Jay and I review financials for the fourth quarter and full year 2019, I want to update you on our internal investigation regarding nonoperating income related to foreign exchange gains and losses. As you know, the company and the Board have taken this matter very seriously. We moved to address it quickly and comprehensively with the help of independent, experienced advisers and forensic accountants. We also communicated proactively to the SEC, and have maintained open dialogue with the commission throughout. As indicated in the press release, our internal investigation is now complete as it relates to the financial statement impacts. This morning, we filed our 2019 Form 10-K, which included audited restated financial statements for full year 2018 and 2017. We also filed our Form 10-Q for the quarter ended September 30, 2019. With these filings, we are now current with our SEC reporting obligations. Jay will discuss in further detail the changes we have made to strengthen and enhance our overall control environment.
各位早安,感謝各位加入我們。在 Jay 和我回顧 2019 年第四季與全年財務之前,我想先向各位更新我們就與外匯損益相關之非營業收入所進行的內部調查進展。如各位所知,公司與董事會對此事極為重視。我們在獨立且具經驗的顧問與法務會計師協助下,迅速且全面地採取行動加以處理。我們也主動與 SEC 溝通,並在整個過程中與委員會保持開放對話。如新聞稿所述,就財務報表影響而言,我們的內部調查現已完成。今天上午,我們已提交 2019 年 Form 10-K,其中包含經審計之 2018 年與 2017 年全年重編財務報表。我們也提交了截至 2019 年 9 月 30 日止季度的 Form 10-Q。透過這些申報,我們目前已符合 SEC 申報義務並維持最新狀態。Jay 將進一步詳細說明我們為強化與提升整體控制環境所做的變更。
Before I shift to a discussion of financial results for the fourth quarter of 2019, I feel it's important to make some comments on the rapidly evolving situation with COVID-19. The coronavirus outbreak continues to challenge communities, relief organizations, health care systems and businesses around the world. At Baxter, we have been active on the front line since its emergence, taking proactive measures to protect employees, aid patients and health care providers affected by the pandemic and maintain global supply of our essential medical products. On the supply front, our manufacturing operations are currently running at planned levels, and our supply chain team is assessing and mitigating possible disruptions around the globe. We are proactively managing our inventory levels, stock levels in warehouses, transportation options and the availability of raw materials and component parts. Given the global nature of the epidemic, we have seen some constraints on a limited number of components and APIs, especially those sourced from China and Italy.
在我轉入討論 2019 年第四季財務結果之前,我認為有必要就 COVID-19 迅速演變的情勢發表一些看法。新冠病毒疫情持續對全球各地的社區、救援組織、醫療體系與企業帶來挑戰。在百特,自疫情出現以來我們一直在第一線積極投入,採取主動措施以保護員工、協助受疫情影響的病患與醫療照護提供者,並維持我們關鍵醫療產品的全球供應。在供應方面,我們的製造營運目前依計畫水準運作,而我們的供應鏈團隊正評估並緩解全球可能的中斷。我們正主動管理庫存水位、倉庫存量、運輸選項,以及原物料與零組件的可得性。鑑於疫情的全球性,我們已在少數零組件與 API(活性藥物成分)上看到一些限制,尤其是來自中國與義大利的來源。
At this time, our team has been able to mitigate those disruptions by deploying existing inventory, providing additional support to our suppliers to help them return to production, using alternate shipping methods to expedite delivery and working with additional suppliers where needed. Our own efforts over the last few years to strengthen and expand our manufacturing supply network further support our position. We will continue to work closely with our regional and global supplier networks to address this ever-evolving situation. And our goal remains to help ensure all of our customers have access to the products they need to the best of our ability. To that end, I'd like to acknowledge the extraordinary actions of our 50,000 Baxter colleagues around the world, have been taken to serve patients and clinicians and help ensure access to our life-saving and life-sustaining products. While we will continue to actively monitor this situation and its potential business disruptions, we remain confident in our long-term underlying strength and innovation pipeline. We will also remain vigilant in exploring the most impactful ways to deploy our capital, including compelling business development opportunities as well as returning value directly to our investors.
目前,我們的團隊已能透過動用既有庫存、為供應商提供額外支援以協助其恢復生產、採用替代運輸方式以加速交付,以及在需要時與其他供應商合作,來緩解這些中斷。我們過去幾年為強化並擴大製造供應網路所做的努力,也進一步支持了我們的有利地位。我們將持續與區域及全球供應商網路密切合作,以因應這個持續演變的情勢。我們的目標仍是盡最大努力協助確保所有客戶都能取得其所需產品。為此,我想肯定全球 50,000 名百特同仁所採取的非凡行動,他們致力於服務病患與臨床人員,並協助確保我們救命與維持生命之產品的可近性。雖然我們將持續密切監控此情勢及其對業務可能造成的中斷,我們仍對長期的基本實力與創新產品線充滿信心。我們也將保持警覺,探索最具影響力的資本運用方式,包括具吸引力的業務發展機會,以及直接回饋投資人價值。
With that, I will make some brief comments on our 2019 performance. As we shared in early January, our Q4 performance reflected Baxter's strongest operational sales growth since the 2015 Baxalta spin-off. Sales increased 7% on a reported basis, 8% at a constant currency and 9% on an operational basis. All 6 of our global business units and 3 geographic segments contributed to this strong top line performance, which was driven in part by our reinvigorated emphasis on innovation. Advancing our new product pipeline will continue to be a fundamental element of our ongoing transformation.
接下來,我將就我們 2019 年的表現做一些簡短評論。如我們在 1 月初所分享的,第四季表現反映出百特自 2015 年 Baxalta 分拆以來最強勁的營運銷售成長。銷售額以報告基礎成長 7%,以固定匯率成長 8%,以營運基礎成長 9%。我們 6 個全球事業單位與 3 個地理區隔皆對此強勁的營收表現有所貢獻,而這部分也受惠於我們重新強化對創新的重視。推進新產品研發管線將持續是我們持續轉型的核心要素。
Our top line performance, combined with a focus on operational excellence and financial discipline, drove adjusted EPS of $0.97, a 37% increase year-over-year. Our fourth quarter performance demonstrated our ability to drive growth across our diversified portfolio by focusing on effectively meeting the needs of patients and providers. Within the quarter, we saw PD patient growth of approximately 7% globally, including low double-digit PD patient growth in the U.S. While we await publication of the final rule from the White House on the Advancing American Kidney Health Initiative, we are actively planning for investments required to increase our U.S. production capacity to meet new patient needs. We anticipate that home PD growth will continue to outpace that of overall ESRD growth.
我們的營收表現,加上對營運卓越與財務紀律的專注,帶動調整後 EPS 達 0.97 美元,年增 37%。第四季表現展現了我們透過聚焦有效滿足病患與醫療提供者需求,推動多元化產品組合全面成長的能力。在本季度內,我們看到全球 PD(腹膜透析)病患人數約成長 7%,其中美國 PD 病患人數成長達低雙位數。儘管我們仍在等待白宮就「推進美國腎臟健康倡議」(Advancing American Kidney Health Initiative)發布最終規則,我們已積極規劃所需投資,以提升美國產能來滿足新增病患需求。我們預期居家 PD 的成長將持續快於整體 ESRD(末期腎臟病)成長。
In addition, during the quarter, we installed more infusion pumps in the U.S. than we have in recent history. Our Spectrum IQ infusion pump has one of the best drug libraries in the world, along with bidirectional EMR integration, and we continue to realize the benefits of innovation across our portfolio. Pharmaceuticals growth in the quarter was enhanced by our growing range of generic injectables. Enhanced momentum in clinical nutrition was fueled in part by our recent OLIMEL N12 and FINOMEL launches. Within Advanced Surgery, we effectively met heightened market demands for FLOSEAL Fast Prep, which launched earlier in 2019. And in Acute Therapies, we continue to successfully roll out our PrisMax platform across geographies. All in all, we are pleased to close out 2019 on such a strong note and are well positioned for sustained momentum as we remain focused on our long-term strategic objectives.
此外,在本季度,我們在美國安裝的輸注幫浦數量高於近年來的任何時期。我們的 Spectrum IQ 輸注幫浦擁有全球最優秀的藥物資料庫之一,並具備雙向 EMR 整合功能;我們也持續在整體產品組合中實現創新所帶來的效益。本季度製藥業務的成長,受惠於我們不斷擴充的學名注射劑產品線。臨床營養的動能提升,部分來自我們近期推出的 OLIMEL N12 與 FINOMEL。在先進外科領域,我們有效滿足了市場對 2019 年稍早推出之 FLOSEAL Fast Prep 的更高需求。而在急性治療方面,我們持續成功地在各地區推動 PrisMax 平台的導入。總體而言,我們很高興以如此強勁的表現為 2019 年畫下句點;在持續聚焦長期策略目標的同時,我們也已為維持動能做好充分準備。
Now I will pass it on to Jay to provide some additional details on the quarter.
接下來我將交給 Jay,請他就本季度提供一些補充細節。
James K. Saccaro - Executive VP & CFO
James K. Saccaro - Executive VP & CFO
Thanks, Joe, and good morning, everyone. As Joe mentioned, our fourth quarter results demonstrate robust operational performance, with solid growth across all 6 global business units and 3 geographic segments.
謝謝你,Joe,各位早安。如 Joe 所提到,我們第四季的結果展現了強勁的營運表現,6 個全球事業單位與 3 個地理區隔皆呈現穩健成長。
Throughout the year, we delivered on our goal of growth through innovation and drove further benefits from our ongoing transformation initiatives. Moving into 2020 and beyond, we will continue to execute on our commercial strategies while also investing in several initiatives to support accelerated growth opportunities. As Joe referenced, we've implemented a number of changes to strengthen and enhance our overall internal control environment. Some of these changes, including utilizing exchange rates in accordance with U.S. GAAP, a daily automated feed of foreign exchange rates from a recognized third party, updated policies on intercompany transaction approvals and select personnel changes, including hiring Karen Leets as our new Treasurer. Karen brings significant treasury experience to Baxter, after having held senior treasury roles at several large corporations. Under her leadership, we've hired another experienced treasury professional in a newly created director role, responsible for treasury governance and controls. Additionally, we've created a treasury controller role within our accounting function and are continuing to add resources as appropriate to improve our financial reporting controls related to treasury activities. While this was clearly disappointing, we are moving forward and continuing to execute on our strategic objectives in support of our goal to deliver industry-leading performance. And our recent results demonstrate the strength of this ongoing transformation.
在整個年度中,我們達成了以創新帶動成長的目標,並從持續推動的轉型計畫中獲得更多效益。展望 2020 年及之後,我們將持續執行商業策略,同時投資多項計畫以支持加速成長的機會。如 Joe 所提及,我們已實施多項變更,以強化並提升整體內部控制環境。其中部分變更包括:依照美國 GAAP 使用匯率、由公認第三方提供之外匯匯率每日自動匯入、更新關於關係企業間交易核准的政策,以及若干人員調整(包括聘任 Karen Leets 擔任新任財務主管〔Treasurer〕)。Karen 曾在多家大型企業擔任資金管理高階職務,為 Baxter 帶來豐富的資金管理經驗。在她的領導下,我們另聘任一位資深資金管理專業人士,擔任新設立的總監職位,負責資金治理與控制。此外,我們也在會計職能中設立資金控管會計主管(treasury controller)職位,並將視需要持續增補資源,以改善與資金活動相關的財務報導控制。雖然這顯然令人失望,但我們正持續向前,並繼續執行策略目標,以支持我們提供業界領先表現的目標。而我們近期的成果也展現了這項持續轉型的實力。
Turning to our fourth quarter and full year 2019 results. Beginning with the fourth quarter, global sales of $3 billion increased 7% on a reported basis, 8% on constant currency and 9% operationally. Our performance in the quarter was primarily driven by Pharmaceuticals as well as Medication Delivery and Advanced Surgery, particularly in the United States. On the bottom line, adjusted earnings increased 37% to $0.97 per diluted share as a result of strong operational performance and ongoing benefit from our business transformation efforts and the lower share count.
接著說明我們 2019 年第四季與全年業績。先從第四季開始,全球銷售額為 30 億美元,按報告基礎成長 7%,按固定匯率成長 8%,按營運基礎成長 9%。本季度表現主要由製藥業務,以及藥物輸送與先進外科所帶動,尤其是在美國市場。在獲利方面,受惠於強勁的營運表現、持續的業務轉型效益以及較低的流通股數,調整後盈餘成長 37%,至每股稀釋後 0.97 美元。
Now I'll walk you through performance by our geographic segments and global business units. Note that for this quarter, constant currency sales growth is equal to operational sales growth for all businesses and geographic segments, except for our Pharmaceuticals business and the Americas region, for which we will provide operational growth in addition to constant currency growth. Additionally, all growth rates represent comparisons to our restated historical financials published this morning.
接下來我將依地理區隔與全球事業單位,帶各位檢視表現。請注意,本季度除製藥業務與美洲地區外,所有業務與地理區隔的固定匯率銷售成長率皆等同於營運銷售成長率;對於製藥業務與美洲地區,我們將在提供固定匯率成長之外,另提供營運成長。此外,所有成長率皆為與我們今早發布之重編後歷史財務數據的比較。
Starting with sales growth for our 3 geographic segments. Sales in the Americas advanced 10% on both the constant currency and operational basis. Sales in EMEA advanced 5% on a constant currency basis. And sales in our Asia Pacific region advanced 9% on a constant currency basis.
先從 3 個地理區隔的銷售成長開始。美洲地區銷售按固定匯率與營運基礎皆成長 10%。EMEA 地區銷售按固定匯率成長 5%。亞太地區銷售按固定匯率成長 9%。
Moving on to performance by global business units. Global sales for Renal Care were $960 million, advancing 2% on a constant currency basis. Performance in the quarter was driven by growth in PD therapies globally with patient volumes advancing approximately 7% year-over-year. Performance was partially offset by lower sales of select in-center HD products, including the bloodlines business exited in early 2019, which negatively impacted sales in the quarter by approximately $12 million.
接著看各全球事業單位的表現。腎臟照護(Renal Care)全球銷售額為 9.60 億美元,按固定匯率成長 2%。本季度表現由全球腹膜透析(PD)治療的成長所帶動,病患量年增約 7%。部分成長被特定院內血液透析(HD)產品銷售下滑所抵銷,其中包括於 2019 年初退出的血液管路(bloodlines)業務,該因素使本季度銷售約減少 1,200 萬美元。
Sales in Medication Delivery of $775 million grew 19% on a constant currency basis. Strong global growth was supported by solid commercial execution across our infusion systems and IV solutions businesses. During the quarter, we did see approximately $10 million of distributor purchases ahead of the U.S. influenza season. The fourth quarter also marked our first quarter of sales of the Starling SV hemodynamic monitoring system obtained as part of the acquisition of Cheetah Medical, which contributed less than $5 million to sales in the quarter.
藥物輸送(Medication Delivery)銷售額為 7.75 億美元,按固定匯率成長 19%。強勁的全球成長,來自我們在輸注系統與靜脈輸液(IV)解決方案業務上的扎實商業執行。本季度我們確實看到約 1,000 萬美元的經銷商在美國流感季前提前採購。第四季也標誌著我們首次認列 Starling SV 血流動力學監測系統的銷售(該產品為收購 Cheetah Medical 所取得),對本季度銷售貢獻低於 500 萬美元。
Pharmaceutical sales were $580 million, increasing 9% constant currency and 10% operationally. Strong international sales in the quarter benefited from increased demand for our hospital pharmacy compounding services. Additionally, global demand for Baxter's generic injectables portfolio contributed to growth in the quarter. Performance was partially offset by expected lower sales of inhaled anesthesia products and Transderm Scop due to enhanced competition. U.S. sales of cyclophosphamide were $38 million in the quarter.
製藥(Pharmaceuticals)銷售額為 5.80 億美元,按固定匯率成長 9%,按營運基礎成長 10%。本季度強勁的國際銷售,受惠於市場對我們醫院藥局調配服務需求增加。此外,全球對 Baxter 學名注射劑產品組合的需求,也推動了本季度成長。部分表現被預期中的吸入式麻醉產品與 Transderm Scop 銷售下滑所抵銷,原因為競爭加劇。本季度美國市場的 cyclophosphamide 銷售額為 3,800 萬美元。
Moving to Nutrition. Total sales were $233 million, increasing 10% on a constant currency basis, in line with our expectations and supported by new product launches in the U.S. and Europe. Sales in Advanced Surgery were $231 million, increasing 10% on a constant currency basis. Performance in this business was driven by strong commercial execution as well as further benefit from competitive supply disruptions. Sales in our Acute Therapies business were $144 million, representing growth of 7% on a constant currency basis. Performance in this business continues to be driven by increased global demand for Baxter's continuous renal replacement therapies, supported by the continued rollout of our PrisMax platform.
接著看營養(Nutrition)。總銷售額為 2.33 億美元,按固定匯率成長 10%,符合我們的預期,並受惠於在美國與歐洲的新產品上市。先進外科(Advanced Surgery)銷售額為 2.31 億美元,按固定匯率成長 10%。該業務表現由強勁的商業執行所帶動,並進一步受惠於競爭對手供應中斷所帶來的影響。急性治療(Acute Therapies)業務銷售額為 1.44 億美元,按固定匯率成長 7%。該業務表現持續由全球對 Baxter 連續性腎臟替代治療(CRRT)需求增加所驅動,並由我們持續推動 PrisMax 平台導入所支持。
Finally, sales in our other category, which primarily includes our contract manufacturing services, were $116 million, a decline of 3% on a constant currency basis, reflecting a challenging comparison to the prior year period.
最後,其他類別的銷售(主要包含我們的委託製造服務)為 1.16 億美元,按固定匯率下滑 3%,反映與去年同期相比的比較基期較具挑戰性。
Moving through the rest of the P&L. Our adjusted gross margin of 45.7% increased 160 basis points over the prior year, benefiting from strong top line performance, favorable mix as well as positive manufacturing variations. Adjusted SG&A totaled $626 million, increasing 5% on a reported basis. Strong sales performance, along with a focus on optimizing our cost structure, drove expense leverage in the quarter. Adjusted R&D spending in the quarter of $153 million decreased 7% on a reported basis versus the prior year period. We continue to see the benefit from our efforts to enhance our processes and optimize our R&D organization while prioritizing strategic investments in our innovation pipeline. Adjusted operating margin in the quarter was 20%, an increase of 270 basis points versus the prior year and above our previous guidance range of 18.5% to 19%. Net interest expense was $20 million in the fourth quarter, an increase of $9 million compared to the prior year driven by lower interest income and increased interest expense from higher outstanding debt balances. Adjusted other nonoperating income totaled $16 million in the quarter. That amount excludes a $755 million noncash charge that we recorded in our GAAP result as a result of the transfer of approximately $2.4 billion of our U.S. pension liabilities to an insurance company through an annuitization transaction in October. The adjusted tax rate in the quarter was 16.5%. Within the fourth quarter, we repurchased approximately $200 million or 2.4 million shares of Baxter stock. For the full year, our repurchases totaled approximately $1.3 billion or 16.5 million shares of Baxter stock.
接著說明損益表其餘項目。我們的調整後毛利率為45.7%,較去年同期提升160個基點,受惠於強勁的營收表現、有利的產品組合以及正向的製造差異。調整後銷售、一般及行政費用(SG&A)合計為6.26億美元,按報告基礎增加5%。強勁的銷售表現,加上聚焦於優化成本結構,帶動本季費用槓桿效益。本季調整後研發(R&D)支出為1.53億美元,按報告基礎較去年同期下降7%。我們持續看到在強化流程與優化研發組織方面努力所帶來的效益,同時優先投入創新管線的策略性投資。本季調整後營業利益率為20%,較去年同期提升270個基點,且高於我們先前18.5%至19%的指引區間。第四季淨利息費用為2,000萬美元,較去年同期增加900萬美元,主因為利息收入下降,以及因未償債務餘額較高而使利息費用增加。本季調整後其他非營業收入合計為1,600萬美元。該金額不包含我們在GAAP結果中認列的7.55億美元非現金費用,此費用係因我們於10月透過年金化交易,將約24億美元的美國退休金負債移轉至一家保險公司所致。本季調整後有效稅率為16.5%。在第四季期間,我們回購了約2億美元、約240萬股的百特(Baxter)股票。全年回購合計約13億美元、約1,650萬股的百特(Baxter)股票。
Turning to full year 2019, sales of $11.4 billion increased by 2% on a reported basis and 5% on both the constant currency and operational basis. On the bottom line, adjusted earnings increased 14% to $3.31 per diluted share. On a full year basis, we generated free cash flow of more than $1.4 billion. While this was below our initial projections, cash flow generation remains a critical priority for Baxter. And as such, we have implemented several actions targeted to improve working capital efficiency. Our focus continues to be on maintaining flexibility for internal and external investments, supporting strategic growth initiatives and returning value to shareholders.
轉到2019年全年,銷售額為114億美元,按報告基礎成長2%,按固定匯率與營運基礎皆成長5%。在獲利方面,調整後盈餘成長14%,至每股稀釋後盈餘3.31美元。以全年計,我們產生超過14億美元的自由現金流。雖然這低於我們最初的預估,但現金流的產生仍是百特的關鍵優先事項。因此,我們已採取多項行動,旨在提升營運資金效率。我們的重點仍在於維持內外部投資的彈性、支持策略性成長計畫,並為股東創造回報。
In particular, given the current market uncertainty regarding COVID-19, we are incredibly focused on maintaining adequate liquidity to withstand scenarios that might emerge, so we are able to continue to pursue our capital allocation strategies. As of the end of February, we have nearly $3 billion of cash on our balance sheet, which includes over $200 million in borrowings from our European revolver, which we have accessed as a precautionary measure. We've also recently renewed the terms of our U.S. revolving credit facility, which provides us with access to $2 billion in credit. While we have not drawn on this facility to date, we are currently able to do so, if necessary.
特別是鑑於目前市場對COVID-19的不確定性,我們高度聚焦於維持充足流動性,以承受可能出現的各種情境,從而能持續推進我們的資本配置策略。截至2月底,我們資產負債表上接近30億美元現金,其中包含我們自歐洲循環信貸額度借入的逾2億美元,這是我們出於預防性考量而動用的。我們也近期更新了美國循環信貸融資的條款,使我們可取得20億美元的信貸額度。雖然截至目前我們尚未動用該額度,但如有需要,我們目前可以動用。
Let me conclude my comments by discussing our near-term financial outlook. As stated in today's press release, given the high degree of uncertainty around potential impacts presented by COVID-19, we are not providing full year 2020 guidance at this time. Depending on how the situation unfolds, we hope to be in a position to provide additional guidance details during our first quarter earnings call, currently scheduled for April 30. Specific to the first quarter of 2020, we expect sales growth of 4% to 5% on a reported basis, and growth of 5% to 6% on both a constant currency and operational basis. For 2020, operational sales will be adjusted for the impact of foreign exchange and the acquisition of Seprafilm. And we expect adjusted earnings, excluding special items, of $0.72 to $0.74 per diluted share for the first quarter.
最後,我以討論我們短期財務展望作結。如同今日新聞稿所述,鑑於COVID-19可能帶來影響的不確定性程度很高,我們目前不提供2020年全年指引。視情況發展而定,我們希望能在第一季財報電話會議(目前排定於4月30日)時,提供更多指引細節。就2020年第一季而言,我們預期銷售額按報告基礎成長4%至5%,按固定匯率與營運基礎皆成長5%至6%。2020年營運銷售將調整外匯影響以及Seprafilm收購案的影響。此外,我們預期第一季調整後盈餘(不含特殊項目)為每股稀釋後0.72至0.74美元。
With that, we can now open the call to Q&A.
接下來,我們現在開放問答。
Operator
Operator
(Operator Instructions) I would like to remind participants that this call is being recorded and a digital replay will be available on Baxter International's website for 60 days at www.baxter.com.
(接線員指示) 提醒各位與會者,本次電話會議將被錄音,並將於百特國際(Baxter International)網站提供為期60天的數位重播,網址為www.baxter.com。
And our first question comes from Pito Chickering from Deutsche Bank.
我們的第一個問題來自德意志銀行(Deutsche Bank)的Pito Chickering。
Philip Chickering - Research Analyst
Philip Chickering - Research Analyst
First one is on your manufacturing side. You talked about in the script that you guys don't believe in issues with the supplies. Can you sort of go into more detail around where the majority of your raw materials are coming from? Sort of what percent of those are sourced through the guys at China? And sort of why is that sort of not a risk in terms of being able to do that to offset from, like, other supplier, (inaudible)? And I have a follow-up after that.
第一個問題是關於你們的製造端。你們在講稿中提到,你們認為供應方面沒有問題。你能否更詳細說明你們大多數原物料的來源?其中有多少比例是透過中國那邊採購?以及為什麼在能夠做到這點、用以抵消例如其他供應商(聽不清)方面,這不算是一個風險?我之後還有一個追問。
Clare Trachtman - VP of IR
Clare Trachtman - VP of IR
Yes. So just to refresh the question because it's a little hard for you -- to hear you, Pito. So I think what you were talking about is just our overall manufacturing, where we're at, where our raw materials are coming from, how confident are we in the supply chain. Is that kind of summarize what you were asking?
好的。我先重述一下問題,因為有點聽不清楚你說話,Pito。我想你問的是我們整體製造的情況、我們目前的狀態、原物料來源,以及我們對供應鏈的信心有多高。這樣是否概括了你的問題?
Philip Chickering - Research Analyst
Philip Chickering - Research Analyst
Yes. Yes, and I apologize, on a cellphone obviously.
是的。是的,抱歉,我顯然是在用手機。
José E. Almeida - Chairman, President & CEO
José E. Almeida - Chairman, President & CEO
Okay. And our raw materials come from a variety of places around the globe. Let me -- because your question has a specificity for COVID-19, I'm sure, and our supply chain. So our electronics come primarily from parts of Europe and China. We're working very diligently and we're getting -- starting to get components out of China. We have good safety stocks. We feel comfortable that towards late spring, we will have enough. For most of our products, we have guaranteed ability of having products sold across the globe. So I'm not that concerned. If things become really difficult in China back to what it was in January and February, then the conversation is different. But today, the way we're seeing the shipping lanes are clearing up, we're getting products into our factories, not -- don't feel they were under tremendous amount of pressure.
好的。我們的原物料來自全球各地多元的來源。讓我—因為你的問題顯然是針對COVID-19以及我們的供應鏈,所以我說明一下。我們的電子零組件主要來自歐洲部分地區以及中國。我們正非常努力地推進,也開始從中國把零組件運出來。我們有充足的安全庫存。我們有信心在春末前後,我們會有足夠的供應。對於我們大多數產品,我們都能確保在全球範圍內供貨與銷售。因此我並不太擔心。如果中國的情況真的又變得非常困難,回到1月和2月那樣,那討論就不同了。但就今天而言,我們看到航運航線正在恢復順暢,我們正把產品運進工廠,並不覺得承受了巨大的壓力。
Now when it comes to IV bags. IV bags, the products are made -- for the U.S., are exclusively made in the U.S. Meaning the raw materials are made in our plant in Arkansas, the bags are made in the Carolinas. And we can also make bags down in Mexico in Cuernavaca. So that is a backup plant that we have set up since Hurricane Maria, and we can get -- we are getting products from there now. We can get products -- more products in the future. So our supply chain is -- we have about probably 20, 25 components in raw materials that we're watching very closely. But we have 24 hours coverage around the globe. Our procurement departments are set in many parts of the world. So at this moment, we feel that between APIs, which are also made in India and China, we have a pretty good grip and the APIs are about the same of the electronics. We're talking about late spring. If things get worse in China, that's a different conversation. But with what we know right now, we are comfortable with inventory levels and we can supply the demand.
現在談到 IV 袋。IV 袋方面,供美國市場的產品是完全在美國製造的。也就是說,原料在我們阿肯色州的工廠生產,袋子在卡羅萊納州製造。另外,我們也可以在墨西哥庫埃納瓦卡生產袋子。因此那是一座我們在瑪麗亞颶風之後建立的備援工廠,我們現在也正從那裡取得產品。未來我們也可以從那裡取得更多產品。所以我們的供應鏈是——我們大概有 20 到 25 項原物料零組件正在非常密切地監控。但我們在全球有 24 小時的覆蓋。我們的採購部門設在世界許多地方。因此在此刻,我們覺得在 API(也在印度與中國生產)之間,我們掌握得相當不錯,而 API 的情況大致與電子零組件相同。我們談的是晚春。如果中國情況惡化,那就是另一個話題了。但就我們目前所知,我們對庫存水位感到安心,也能供應需求。
Philip Chickering - Research Analyst
Philip Chickering - Research Analyst
Great. And then the follow-up question is going to be a non-COVID-19. Can you walk us through the manufacturing capabilities of THERANOVA at this point? How fast can that be expanded, and whether it's new lines on the manufacturing sites? And how much would each of those cost? And how many of units would those create?
很好。接下來的追問會是非 COVID-19 的問題。你能否帶我們了解一下目前 THERANOVA 的製造能力?這個產能能以多快速度擴充?是否是在製造據點新增產線?每一條產線大約要花多少成本?而每條產線能新增多少單位產量?
José E. Almeida - Chairman, President & CEO
José E. Almeida - Chairman, President & CEO
So Pito, we have the ability today to make turnover, okay? We can make high single-digit millions of -- mid-single digits in the millions of that, okay? We are starting in October converting production lines from our current Revaclear to THERANOVA, meaning the lines will be able to make either one of them. And I think by the time we finished the conversion for the globe, we're going to be able to supply probably close to 30 million units -- 28 million to 30 million units, okay? This is as we know today. We can always make investment plans for more capacity. As you know or you may not know, we manufacture our own equipment, our spinnerets, our spindles and spinning equipment, and how we bundle the fibers in this very proprietary, great product that we currently design and are making outside of the U.S. today. So that's our capacity. And we're prepared, by the way, once the period of 2 years of demonstration of the add-on payment, what's called TPNIES. I got corrected in Washington last week by somebody at CMS. It's not TPNIES. It's TPNIES. We can accelerate investment and we can produce more than 30 million, if needed be.
所以,Pito,我們今天有能力做切換(turnover),好嗎?我們可以做到數百萬級的高個位數——大概是數百萬級的中個位數,對吧?我們從 10 月開始把現有 Revaclear 的生產線轉換為 THERANOVA,也就是說,這些產線將能夠生產其中任何一種。我想等到我們完成全球的轉換時,我們將能供應大概接近 3,000 萬個單位——2,800 萬到 3,000 萬個單位,對吧?這是以我們今天所知的情況。我們隨時都可以制定投資計畫來增加更多產能。如你所知或你可能不知道,我們自行製造設備、噴絲頭(spinnerets)、紡錘與紡絲設備,以及我們如何把纖維束成這個非常專有、非常出色的產品;目前我們的設計與製造是在美國以外進行。所以這就是我們的產能。順帶一提,在所謂 TPNIES 的加成支付(add-on payment)兩年示範期結束後,我們也已做好準備。上週在華盛頓,有位 CMS 的人士糾正了我。不是 TPNIES。是 TPNIES。如果有需要,我們可以加速投資,並把產量提高到超過 3,000 萬。
Operator
Operator
Robbie Marcus with JPMorgan.
摩根大通(JPMorgan)的 Robbie Marcus。
Robert Justin Marcus - Analyst
Robert Justin Marcus - Analyst
So I imagine everyone is very curious about what life will be like under COVID-19. You pulled guidance, but we are almost completely through the first quarter here. So I was wondering if you could comment on trends you're seeing in the first quarter in terms of different positives or negatives in the business and any actions you're seeing from the hospitals in Europe and U.S. as they prepare for what's to come here over the next few weeks.
我想大家都非常好奇在 COVID-19 之下的生活會是什麼樣子。你們撤回了財測指引,但我們現在幾乎已經走完整個第一季了。所以我想請你評論一下第一季你們看到的趨勢:就業務而言有哪些正面或負面的變化?以及你們是否看到歐洲與美國的醫院在為接下來幾週將要發生的事情做準備時採取了哪些行動?
José E. Almeida - Chairman, President & CEO
José E. Almeida - Chairman, President & CEO
Robbie, we will -- let me get part of your question. And Jay is also here, he can chime in. We are seeing buying patterns that you see usually in -- with this kind of situation. We have only to compare in heavy flu seasons, and some of us remember, back in 2003, SARS, okay? So we have buying patterns that go from people not understanding what's happening, all of a sudden, stockpiling going around everywhere, okay? So Baxter is at the front line of treating patients with acute respiratory and acute generalized infection with our CRRT, continuous renal replacement therapy, our fluids, our antibiotics, our pumps. So we feel that right now, we are seeing buying patterns that are starting to get more coherent with an outbreak of something like the COVID-19 that we saw probably halfway through the first quarter because halfway through the first quarter, China was more in focus in -- what we saw in China. And remember, not only we're in the front lines for treatment of diseases such as this but also, we are in the chronic treatment business, which we need to deliver products to people's homes. So we saw in China an acceleration of purchasing for PD paired to new dialysis products.
Robbie,我們會——讓我先回答你問題的一部分。Jay 也在這裡,他也可以補充。我們看到的採購模式,通常就是你在——在這種情況下會看到的那種。我們只能拿嚴重流感季來比較,而有些人還記得,2003 年的 SARS,對吧?所以我們看到的採購模式是:人們一開始不理解發生了什麼事,突然之間,各地開始囤貨,對吧?Baxter 站在第一線,透過我們的 CRRT(連續性腎臟替代治療)、輸液、抗生素與幫浦,治療急性呼吸道與急性全身性感染的病患。因此我們覺得,就目前而言,我們看到的採購模式開始更符合像 COVID-19 這類疫情爆發時的情況;我們大概在第一季過半時就看到了,因為第一季過半時,中國成為更受關注的焦點——我們看到的是中國的情況。而且請記得,我們不僅在這類疾病治療的第一線,同時我們也在慢性治療業務中,需要把產品送到人們家中。所以我們在中國看到,PD(腹膜透析)相關的採購加速,並搭配新的透析產品。
And then what we've seen in the U.S., probably it's going to go through the same thing. We're getting calls from state government, not only the Feds, but also the state government. Countries asking -- placing orders for stockpile of products. So we're starting to see the volume of those orders picking up. We're very -- we've been very judicious because we don't have, at this moment, a capacity restriction, but capacity is all relative. If you go ahead and start buying significant amounts by unit, by hospitals, more than what we can make, we will not be able to supply our business. So we think we're well equipped to supply the world with the products that we need and of the products we have. And we are not -- we have a few products that may go in allocation just as protection. But we have today the major IV business, IV solutions. We don't have any allocations of that. We are prepared to supply the market and naturally activate our backup plans that we have put in place since Maria.
接著我們在美國看到的,可能也會走同樣的路徑。我們接到州政府的來電,不僅是聯邦政府,也包括州政府。各國在詢問——下單採購產品以建立戰備庫存(stockpile)。所以我們開始看到這些訂單的量在增加。我們非常——我們一直非常審慎,因為此刻我們沒有產能限制,但產能是相對的。如果各家醫院開始以單位計大量採購,超過我們能生產的量,我們就無法供應我們的業務。因此我們認為,我們已具備良好條件,能以我們需要的產品、以及我們所擁有的產品來供應全球。而且我們不會——我們有少數產品可能會進入配給(allocation),作為一種保護措施。但我們目前的主要 IV 業務、IV 溶液,並沒有任何配給。我們已準備好供應市場,並自然地啟動自瑪麗亞颶風以來我們所建立的備援計畫。
In terms of the quarter, we're giving guidance a few weeks before we close the quarter. So as I said, we saw 50 patterns in the first quarter. And I think it shows the resilience of our business through a process like this because we do have products used in all sorts of different products -- different settings from the home to the acute side to the more long-term care as well as for nonelective and elective procedures.
就季度而言,我們是在季度結束前幾週提供指引。所以如我所說,我們在第一季看到了 50 種模式。我認為這顯示了我們業務在這類過程中的韌性,因為我們確實有產品會在各式各樣的情境中使用——從居家到急性照護端,再到較長期照護,以及非選擇性與選擇性手術。
Jay, anything?
Jay,有什麼要補充的嗎?
James K. Saccaro - Executive VP & CFO
James K. Saccaro - Executive VP & CFO
No. Joe, I think that's a great commentary. And you described the resilience and the durability of the portfolio. We have a number of product lines, which benefit in this kind of a scenario like acute IV, some of the antibiotics, as Joe described. And then we're watching very carefully our anesthesia and Advanced Surgery businesses, which are more related to actual operating procedures that take place in hospitals. So that's one area that we're watching very carefully. But generally speaking, this is a very durable portfolio that we have.
沒有。Joe,我覺得那是很棒的評論。而且你描述了投資組合的韌性與耐久性。我們有多條產品線,在這類情境下會受惠,例如急性 IV、一些抗生素,如 Joe 所描述。然後我們也非常密切關注麻醉與先進外科(Advanced Surgery)業務,這些業務與醫院實際進行的手術處置更相關。所以那是我們非常密切關注的一個領域。但整體而言,我們擁有的是一個非常耐久的產品組合。
Robert Justin Marcus - Analyst
Robert Justin Marcus - Analyst
Great. And maybe just one follow-up. People are starting to worry about the impact to capital equipment sales. So with you set to launch a new pump system, which could actually be in high demand, do you expect any impact to that or to your PD cyclers over the next few weeks and months?
很好。也許再追問一個問題。大家開始擔心對資本設備銷售的影響。因此,隨著你們準備推出一套新的幫浦系統,而它實際上可能需求很高,你們預期未來幾週到幾個月,這方面或你們的 PD 透析循環機(cyclers)會受到任何影響嗎?
José E. Almeida - Chairman, President & CEO
José E. Almeida - Chairman, President & CEO
Very different dynamics, Robbie. Very different dynamics. First of all, at hospitals today in the U.S., the priority is to treat potential patients coming in. I don't think we'll change dramatically their buying patterns for capital in the midterm. But in the short term, it may alter their priorities. Not that we're not going to be able to sell the pumps. We probably will sell them and we'll probably supply product to customers, who today are impacted by the Class 1 recall of our competitor. But that may change a little bit of sequence looking at the priorities that we are currently putting into place. Remember, we're sending service personnel to hospitals, but I don't think we're going to be sending a bunch of people to install pumps now into hospitals. So it may shift a couple of months here and there, but I don't think the pattern of capital by -- as we know today, will change in the midterm to the long term. It will change in the short term because the priorities of the hospital are to treat the patients.
動態非常不同,Robbie。動態非常不同。首先,在美國,醫院目前的優先事項是治療可能進來的病患。我不認為他們在中期會大幅改變資本採購模式。但在短期內,可能會改變他們的優先順序。並不是說我們就賣不出這些幫浦。我們很可能會賣出去,也很可能會向目前受到競品 Class 1 召回影響的客戶供貨。但就我們目前正在採取的優先事項來看,順序可能會稍微調整。請記得,我們會派服務人員到醫院,但我不認為我們現在會派一大堆人去醫院安裝幫浦。所以可能會前後挪動幾個月,但我不認為就我們目前所知,資本採購的模式在中期到長期會改變。短期會改變,因為醫院的優先事項是治療病患。
On PD, it's a different conversation. PD is actually the safe place to be, which is the home. Imagine putting patients in a clinic with 5, 7 other very ill patients with diabetes, sometimes insufficiency and with the kidneys not functioning, and going to a clinic in this type of outbreak, it is really dreadful. So I would say that there's a great compelling reason for the peritoneal dialysis modality to take shape and be something strong going forward. I'm not saying right now, but I think this actually reinforces the AAKHI prerogative that the government had on having people treated at home. This is another added benefit of the home treatment.
至於 PD,那是另一個話題。PD 其實是最安全的地方,也就是家中。想像把病人放在診所裡,和另外 5、7 位病得很重的病人一起,其中有糖尿病,有時還有功能不全、腎臟無法運作;在這種疫情爆發下還要去診所,真的非常可怕。所以我會說,腹膜透析這種治療模式有非常強的理由會逐步成形,並在未來成為更強勢的選項。我不是說就是現在,但我認為這其實強化了政府推動 AAKHI、讓民眾在家接受治療的主張。這是居家治療的另一項額外好處。
Operator
Operator
Bob Hopkins of Bank of America.
美國銀行(Bank of America)的 Bob Hopkins。
Robert Adam Hopkins - MD of Equity Research
Robert Adam Hopkins - MD of Equity Research
Two quick questions. So it sounds like from your commentary that you've got some products where you're seeing increased demand, like you do in a heavy flu season. In some products, you're seeing a decrease in demand currently. I'm just curious kind of directionally from where you sit today, does this overall feel like a net neutral to your business as far as you can tell right now?
兩個簡短問題。所以聽起來從你們的評論來看,你們有一些產品的需求正在增加,就像流感嚴重季節時一樣。而在某些產品上,你們目前看到需求在下降。我只是好奇,就你們現在所處的位置、就方向性而言,整體看起來目前對你們的業務是否大致是淨中性(net neutral)?
José E. Almeida - Chairman, President & CEO
José E. Almeida - Chairman, President & CEO
It's tough to say, Bob. That's the reason why we are not putting long-term 2020 guidance out there because we need to figure this thing up. As I said, the buying patterns are really strange. We're getting orders for our CRT equipment. They are in excess of anything we've ever seen, okay? We also have a pretty healthy Advanced Surgery business. So we don't understand some of the patterns today. I have to imagine with the changes in procedures in hospitals, some of our business will be impacted like anesthesia, for instance. You have less procedures and surgery. And on the other hand, we have significant amount of business in the ICU. So I cannot give you an answer precisely what -- if this is a net neutral or not. We're going to have to wait. We hope by April -- end of April when we announce our first quarter results, we have either guidance for the rest of the year or have a better understanding of what's happening at the moment.
很難說,Bob。這就是為什麼我們沒有提供 2020 年的長期財測指引,因為我們需要把這件事弄清楚。如我所說,採購模式真的很奇怪。我們收到 CRT 設備的訂單。其數量超過我們過去見過的任何情況,好嗎?我們的先進外科業務也相當健康。所以我們目前不太理解某些模式。我必須想像,隨著醫院處置方式的改變,我們部分業務會受到影響,例如麻醉。手術與外科處置變少。另一方面,我們在 ICU 也有相當可觀的業務。所以我無法精確回答你——這是否是淨中性。我們必須再觀察。我們希望到 4 月——4 月底我們公布第一季結果時,我們要嘛能給出今年剩餘期間的指引,要嘛能對目前發生的事情有更好的理解。
Robert Adam Hopkins - MD of Equity Research
Robert Adam Hopkins - MD of Equity Research
Okay. And then one quick follow-up. I'm really curious as to what you're seeing in China in the Advanced Surgery business. Are you seeing kind of a return to sort of stabilization in procedures in China at this point? Just kind of curious what you're seeing there in that business in particular.
了解。然後再一個簡短追問。我很想知道你們在中國的先進外科業務看到什麼情況。就目前而言,你們是否看到中國的手術量有回到某種程度的穩定?只是好奇你們在那塊業務,特別是那個業務上看到的狀況。
James K. Saccaro - Executive VP & CFO
James K. Saccaro - Executive VP & CFO
That's a very small business for us. So I think on an annual basis, we're talking single-digit millions. So it's very difficult for us to comment on procedure volumes in China, given the small size of that business. The largest business in China for us is our renal business, which is a different kind of business and really not an illustration of what's happening in hospitals.
那對我們來說是非常小的業務。所以我想以年度來看,我們談的是個位數百萬美元的規模。因此,鑑於那塊業務規模很小,我們很難就中國的手術量發表評論。我們在中國最大的業務是腎臟相關業務,那是不同類型的業務,也不太能用來反映醫院裡正在發生什麼。
Robert Adam Hopkins - MD of Equity Research
Robert Adam Hopkins - MD of Equity Research
Okay. I was just trying to get a sense for trends in hospitals in China as they hopefully come out the other side of this.
了解。我只是想掌握一下中國的醫院趨勢,因為他們希望能從這件事的另一端走出來。
José E. Almeida - Chairman, President & CEO
José E. Almeida - Chairman, President & CEO
Yes.
是的。
Operator
Operator
And our next question comes from David Lewis with Morgan Stanley.
下一個問題來自摩根士丹利(Morgan Stanley)的 David Lewis。
David Ryan Lewis - MD
David Ryan Lewis - MD
Maybe, Jay, a couple of quick ones for you. We didn't get segment guidance for the first quarter, so I just wonder if you could help us. If COVID has been largely limited impact -- or it sounds more neutral impact so far for the first quarter. Can you just bridge us from the first quarter guidance, 5% to 6%? Obviously, the fourth quarter, very, very strong. First quarter is anniversarying an easier comp. So just headwinds and tailwinds we should be thinking about to sort of -- to think about the fundamental momentum deceleration in the first quarter? What businesses are stronger, what businesses are weaker? Or what dynamics changed fourth to first? Just so we can kind of get the bridge. That would be super helpful. Then one follow-up.
Jay,或許有幾個簡短問題想請教你。我們沒有拿到第一季的分部指引,所以想請你協助一下。如果 COVID 的影響在第一季大致上仍然有限——或者聽起來到目前為止更偏中性影響。你能否把第一季 5% 到 6% 的指引幫我們做個銜接(bridge)?顯然第四季非常、非常強。第一季是在一個比較容易的比較基期上。所以在思考第一季基本動能放緩時,我們應該考量哪些逆風與順風?哪些業務更強、哪些業務更弱?或者第四季到第一季之間有哪些動態改變?讓我們可以把這個銜接理清楚。那會非常有幫助。然後再一個追問。
James K. Saccaro - Executive VP & CFO
James K. Saccaro - Executive VP & CFO
Sure. Overall, looking at the fourth quarter, as we've said in the past, and David, you and I have discussed, we were very pleased with the performance across the portfolio. We saw strength in every one of our geographic regions. We also saw strength across the business portfolio in terms of great Medication Delivery sales, great sales in each of the portfolio. So very strong quarter. There were a couple of onetime components in place in the fourth quarter. So we did see some buy-in from distributors related to our flu business. We did have some benefit on our Advanced Surgery business relative to competitors being off the market, roughly $15 million.
當然。整體來看第四季,正如我們過去所說的,而且 David,你我也討論過,我們對整個產品組合的表現感到非常滿意。我們在每一個地理區域都看到強勁表現。我們也在業務組合各方面看到強勁動能,包括藥物輸送(Medication Delivery)銷售表現非常出色,以及各個產品組合的銷售都很亮眼。所以這是一個非常強勁的季度。第四季有幾個一次性因素。因此,我們確實看到經銷商針對我們流感業務有一些提前備貨(buy-in)。另外,由於競爭對手暫時退出市場,我們的先進外科(Advanced Surgery)業務也獲得了一些利多,約1,500萬美元。
There were some accounting adjustment true-ups at the end of the year, perhaps around $10 million or so. So we don't see a markedly different trend going from Q4 to Q1. we will see -- like I said, given the strength of the Medication Delivery, that business will come down a little bit, but we still expect to have a solid first quarter in that area. So no markedly different trends. And frankly, if you think about our aspirations that we've talked about over the long term, this Q1 guide is very consistent with what we've seen and shared in the past. So like I said, there were a couple of specific items that -- because we're not a 9% growth company at this stage, so there's a couple of specific items that accentuated the great performance in Q4 that we don't expect to repeat in Q1. And really, that's the primary driver. No real change in fundamentals.
年底也有一些會計調整的追溯修正(true-ups),大概約1,000萬美元左右。因此,從第四季到第一季,我們不認為會出現顯著不同的趨勢。我們會看到——如我所說,鑑於藥物輸送業務的強勁表現,該業務會稍微回落一些,但我們仍預期該領域第一季會有穩健表現。所以沒有顯著不同的趨勢。坦白說,如果你想想我們長期以來談到的目標與企圖心,這次第一季的指引與我們過去看到並分享的內容非常一致。所以如我所說,有幾個特定項目——因為我們現階段並不是一家9%成長的公司——有幾個特定項目讓第四季的優異表現更為突出,而我們不預期這些會在第一季重複出現。而這確實是主要驅動因素。基本面沒有真正的改變。
David Ryan Lewis - MD
David Ryan Lewis - MD
Okay. And then, Jay, just a related question, both for the first quarter and for the year. So EPS guidance for the first quarter, could you just give us the headwinds and tailwinds, first quarter '19 to first quarter '20, just given the guidance is relatively flattish? And then for 2020, there may be some revenue impact for 2020, positive or negative. Can you just help us understand if there is a negative impact, how we should be thinking about the drop-through or the kind of spending activities that are going on inside Baxter now to support customers?
好的。接著,Jay,再問一個相關問題,涵蓋第一季以及全年。關於第一季的每股盈餘(EPS)指引,鑑於指引相對持平,你能否說明一下從2019年第一季到2020年第一季的順風與逆風因素?另外,對於2020年,營收可能會受到一些正面或負面的影響。你能否協助我們理解:如果有負面影響,我們應該如何看待其對獲利的落底傳導(drop-through),或是 Baxter 目前在內部為了支援客戶所進行的各類支出活動?
James K. Saccaro - Executive VP & CFO
James K. Saccaro - Executive VP & CFO
Sure. As it relates to Q1 year-over-year, you're right, as we look at our Q1 of 2019, we had $0.75 roughly in earnings per share, and our current guidance is $0.72 to $0.74. The primary driver is really not related to operational performance. I would say the #1 driver year-over-year is tax rate difference. Last year, we had a very large FAS 123R benefit in the first quarter of the year. We also recorded certain other income in the first quarter, which you can see in our restated financial tables. If we were to adjust for those items, I think it's roughly a $0.06 impact. So what you would see is the sales growth, along with some slight operating margin improvement in the first quarter dropping through, and that's really what drives the performance improvement, offset by some of those financial items that I just referenced.
當然。就第一季年對年而言,你說得沒錯;回看2019年第一季,我們每股盈餘大約是0.75美元,而目前的指引是0.72到0.74美元。主要驅動因素其實與營運表現無關。我會說年對年最大的驅動因素是稅率差異。去年第一季我們有一筆非常大的 FAS 123R 稅務利益。我們也在第一季認列了其他特定收入,你可以在我們重編的財務表格中看到。如果把這些項目調整掉,我認為影響大約是0.06美元。因此你會看到,銷售成長加上第一季些微的營業利益率改善所帶來的貢獻,推動了績效改善,但被我剛才提到的一些財務項目所抵銷。
As we look to the balance of the year, our #1 priority as an organization is to fulfill the mission of the company: saving and sustaining lives. And that means getting product to our customers consistently and reliably. What we're seeing is there are situations where there are some extra costs required from a supply chain standpoint to ensure the continuity of supply, to ensure we're getting critical raw materials out of impacted geographies, and we will spend to support that. So I would expect that. We had some very disciplined targets on supply chain spending. But there will be some spending related to supporting our customers and ensuring consistency of supply. We've got a lot of work that's ongoing in terms of enhancing cash flow, but we will also be really thoughtful about carrying extra inventory in the coming months. Because at the end of the day, we have to have sufficient supply, we have to do everything we can to ensure that. And so we will have -- we will carry some extra inventory of critical products and products we think are likely to be stockpiled in the event of a broader-scale pandemic. So Dave, as you can imagine, there are a lot of moving pieces as we look at the coronavirus in different manifestations that this can take, and so we are prioritizing serving our customers over just about everything else. We're also focused on ensuring the safety of our employees. So those are a few comments.
展望今年其餘時間,作為一個組織,我們的首要任務是履行公司的使命:拯救並維持生命。這意味著要持續且可靠地把產品交付給客戶。我們看到在某些情況下,為了確保供應連續性、確保能從受影響的地區取得關鍵原物料,從供應鏈角度需要承擔一些額外成本,而我們會投入資源來支援。所以我預期會有這樣的支出。我們原本對供應鏈支出有一些非常嚴謹的目標。但確實會有一些與支援客戶、確保供應一致性相關的支出。我們也有許多提升現金流的工作正在進行,但同時在未來幾個月,我們也會非常審慎地考量持有額外庫存。因為歸根結底,我們必須有充足供應,必須盡一切努力確保這一點。因此,我們會——我們會增加一些關鍵產品的額外庫存,以及我們認為在更大規模疫情(pandemic)發生時可能被囤貨的產品。所以 Dave,如你所想,面對冠狀病毒在不同情境下可能出現的各種發展,我們有很多變動因素需要考量,因此我們把服務客戶放在幾乎所有事情之上。我們也專注於確保員工的安全。以上是一些補充說明。
Operator
Operator
Matt Taylor from UBS.
UBS 的 Matt Taylor。
Matthew Charles Taylor - Equity Research Analyst of Medical Supplies & Devices
Matthew Charles Taylor - Equity Research Analyst of Medical Supplies & Devices
So I just wanted to clarify 2 things on your comments on inventory and supplying customers currently. Are you starting to run towards higher inventory levels? It didn't seem like it from your commentary. And then in terms of people stockpiling, are you starting to ration any product? Or how are you managing your inventory to make sure that you're going to have enough if this does get much worse?
我想釐清你們關於庫存以及目前供應客戶的評論中的兩點。你們是否開始朝更高的庫存水位前進?從你的說法聽起來似乎不是。另外,就人們囤貨而言,你們是否開始對任何產品進行配給(ration)?或者你們如何管理庫存,以確保如果情況惡化很多,你們仍會有足夠供應?
James K. Saccaro - Executive VP & CFO
James K. Saccaro - Executive VP & CFO
So I'll take the inventory question and Joe can take the question regarding customer stockpiles. On inventory, we are looking to build inventory levels of critical products wherever possible. Now in some cases, that's not possible because we are running full tilt today. But in cases where we do have the opportunity to think, first of all, creatively about where we locate our inventory around the globe but also, are we running the facilities that could support inventory builds at their highest levels, Matt, we have to be prepared for disruption. We have to be. And so the best way that we know to do that is to build up some extra inventory, so that to the extent that disruptions do occur, we are prepared and ready. So that's really our philosophy. You'll see it when we talk about Q1 cash flow, but that's something that we're watching very carefully, and we're absolutely willing to do and carry in the short term until this situation corrects itself.
我先回答庫存問題,至於客戶囤貨的問題由 Joe 來回答。在庫存方面,我們正盡可能提高關鍵產品的庫存水位。當然在某些情況下這不可能,因為我們目前產線已經全速運轉。但在我們有機會的地方,首先,我們會更有創意地思考如何在全球各地配置庫存;同時也會評估,那些能夠支援庫存建立的工廠是否已在最高產能水位運行。Matt,我們必須為供應中斷做好準備。我們必須如此。因此,我們所知道最好的方式就是建立一些額外庫存,這樣一旦真的發生中斷,我們就能有所準備並隨時應對。這就是我們的理念。當我們談到第一季現金流時你會看到這點,但這是我們非常密切關注的事項;而且在短期內,直到情況自行修正之前,我們絕對願意這麼做並承擔持有庫存。
Joe, you want to talk about customer stockpile?
Joe,你要談談客戶囤貨嗎?
José E. Almeida - Chairman, President & CEO
José E. Almeida - Chairman, President & CEO
Sure. Sure. Matt, we limit hoarding of inventory. Because otherwise you're going to have hospital systems in the U.S. going out and buying more antibiotic, more this, more that. And we are -- we have a control tower approach, where we look at everybody's consumptions and we will supply everyone with their needs. What we want to prevent is people buying months of inventory at a time. They don't even have a place to store. These are bulky items. So we prefer to do our inventory ourselves. We store things ourselves. Our operations today -- Bob Reed runs our operations and supply chain for the company, and is being very thoughtful about how we -- where we put the products. We are starting production lines as a backup. For instance, we started production line in Mexico for the U.S., that is going to be producing millions of bags for the U.S. We have other things that we are doing, just in case. But remember, we want to make sure that everybody gets what they need, and not 1 customer or 2 customers who put in the order first. So we're triaging things. We're making sure that our U.S. system, through Heather Knight, is doing a great job in making sure everybody gets what they need. So we're not rationing. We're not allocating everything. What we're doing is just simply making sure the orders are rational and we'll be able to ship them correctly where people need.
當然。當然。Matt,我們會限制囤積庫存。因為否則美國的醫院體系就會到處去買更多抗生素、更多這個、更多那個。而我們——我們採用「控制塔」的方法,會查看每個人的耗用量,並依需求供應每一位客戶。我們想要避免的是有人一次買好幾個月的庫存。他們甚至沒有地方可以存放。這些都是體積龐大的品項。所以我們更傾向由我們自己來管理庫存。我們自己存放物資。我們目前的營運——Bob Reed負責公司營運與供應鏈,並且非常審慎地思考我們——把產品放在哪裡。我們也在啟動備援的生產線。例如,我們在墨西哥為美國啟動了一條生產線,將為美國生產數百萬個袋子。我們也在做其他事情,以備不時之需。但請記住,我們要確保每個人都能拿到他們需要的,而不是只有1個或2個最先下單的客戶。所以我們在做分級處理。我們也確保我們的美國體系在Heather Knight的帶領下做得非常好,確保每個人都能得到所需。所以我們不是在配給。我們也不是把所有東西都做配額分配。我們做的只是確保訂單是合理的,並且能把貨正確地運送到需要的人那裡。
The same thing with PrisMax. For instance, the Prismaflex, our CRT machines, you have countries putting orders for hundreds of those, "Well, hang on a minute. Why do you need hundreds? You have less beds than another country." So we're making sure that we made and sold more CRT machines than we ever did in a period of time, but we need to make sure that we can make them, their component lead times, their components were -- we're making sure that we get the supply chain coming in right. The supply chain comes from China and other places, we're making sure that we're doing things right. So we're here to serve our customer. Our mission is so important to us. It's sometimes tough to comprehend looking from the outside, from finance community, how much our employees are committed to our mission. And we'll do everything we can to make sure everyone has what they need.
PrisMax也是一樣。例如Prismaflex,我們的CRT機器,有些國家一下子下單要數百台,「等等。你為什麼需要數百台?你的病床數比另一個國家還少。」所以我們確保在一段時間內,我們製造並銷售的CRT機器比以往任何時期都多,但我們也必須確保我們有能力生產——其零組件交期、零組件——我們正在確保供應鏈能正確到位。供應鏈來自中國和其他地方,我們確保我們把事情做對。所以我們在這裡是為了服務客戶。我們的使命對我們非常重要。有時候從外部、從金融圈的角度來看,可能很難理解我們的員工對使命的投入程度有多深。我們會盡一切所能,確保每個人都能得到他們需要的。
Matthew Charles Taylor - Equity Research Analyst of Medical Supplies & Devices
Matthew Charles Taylor - Equity Research Analyst of Medical Supplies & Devices
Maybe I can just ask one follow-up. And I appreciate all the comments on mission, and it is very important right now. The European situation is very fluid. You commented a little bit on China and how that's returned to normal, so that's encouraging. Was wondering if you could give us any color about what's going on, on the ground in your businesses in Italy or other places, where we're seeing infections rise and what that might mean for the U.S.
也許我可以再追問一個問題。我很感謝你們對使命的所有評論,而這在現在確實非常重要。歐洲的情勢變化非常快。你稍微提到中國以及那邊如何回到正常,這令人鼓舞。想請問你能否提供一些第一線的情況,關於你們在義大利或其他地方的業務現況——我們看到感染數上升——以及這對美國可能意味著什麼。
José E. Almeida - Chairman, President & CEO
José E. Almeida - Chairman, President & CEO
First of all, we cannot take China situation for granted because a lot of that has to do with isolation. I think there are papers out there. There was a paper that I read yesterday from the Imperial College in London, talking about that communicable nature of the disease, can spread again. So we are not taking anything for granted. We're very cautious. Our daily calls with our locations always stress the safety of our employees first and servicing the patients as well. So when it comes to Italy, we have special letters that we give to employees because we make products in Italy, primarily in Lombardy area. We have 3 plants there, and we're making fluids and we're making equipment there, and we're making sure the plants have -- are staffed properly. And so far, we've not -- have had much disruption to those plants, and the crossing of the border for supplies are -- is happening. So, so far, so good. And Italy is really the hotspot at the moment as well as Spain. We have a factory in Spain, primarily supplying the Spanish market and some of the south of Europe market. We also have plants in England. All of these plants are operating, as we say, with a sense of normalcy, which is kind of not normalcy because everybody has very heightened attention to everything. And this is just to tell you how committed our people are because they live in their homes and going to work every day in plants in North Carolina, in Alabama, in England, in Australia, everywhere in the world, China, 5 plants in China, they all are operating with the normalcy that you would expect under significant stress on the -- by the outside world and by the news channels and everything that's happening around them.
首先,我們不能把中國的情況視為理所當然,因為那很大程度與隔離措施有關。我想外面有一些研究論文。我昨天讀到一篇倫敦帝國學院的論文,談到這種疾病的傳染性,可能會再次擴散。所以我們不會把任何事情視為理所當然。我們非常謹慎。我們每天與各據點通話時,總是強調員工安全第一,同時也要服務病患。談到義大利,我們會給員工特別的信函,因為我們在義大利生產產品,主要在倫巴底地區。我們在那裡有3座工廠,生產輸液以及設備,並確保工廠——人力配置充足。到目前為止,我們的工廠並未——受到太大干擾,而跨境取得供應——也仍在進行。所以目前為止一切都還不錯。而義大利目前確實是熱點,西班牙也是。我們在西班牙有一座工廠,主要供應西班牙市場以及部分南歐市場。我們在英格蘭也有工廠。所有這些工廠都在運作,我們說是以某種「正常」的狀態運作——這其實不太算正常,因為每個人對所有事情都高度警覺。我提這些只是想告訴你,我們的人有多投入:他們住在家裡,卻每天到工廠上班——北卡羅來納、阿拉巴馬、英格蘭、澳洲、世界各地、中國(中國有5座工廠)——在外界與新聞頻道帶來的巨大壓力,以及周遭發生的一切之下,他們仍以你在高度壓力下所能期待的「正常」狀態在運作。
Operator
Operator
Danielle Antalffy with SVB Leerink.
SVB Leerink的Danielle Antalffy。
Danielle Joy Antalffy - MD of Medical Supplies & Devices and Senior Analyst
Danielle Joy Antalffy - MD of Medical Supplies & Devices and Senior Analyst
I hope everyone is staying healthy during these crazy times and safe. Just a quick question, a non-COVID-19-related question. On the Medication Delivery business, very strong operational sales growth in Q4. Obviously, that's not likely to continue. But can you help us understand how sustainable any momentum that you have in the Medication Delivery business is into 2020 and beyond, and the different drivers of the strong growth that we've been seeing there in the back half of the year?
希望大家在這段瘋狂的時期都能保持健康並注意安全。我有個簡短問題,一個與COVID-19無關的問題。在藥物輸送(Medication Delivery)業務方面,第四季的營運銷售成長非常強勁。顯然這不太可能持續。但你能否幫我們理解,你們在藥物輸送業務上的動能在2020年及之後有多可持續,以及我們在下半年看到的強勁成長背後有哪些不同的驅動因素?
José E. Almeida - Chairman, President & CEO
José E. Almeida - Chairman, President & CEO
Danielle, just a bit of color on the business. And Jay, if you want to chime in, please do.
Danielle,我補充一些這項業務的背景。Jay,如果你想補充,也請加入。
James K. Saccaro - Executive VP & CFO
James K. Saccaro - Executive VP & CFO
Sure.
好的。
José E. Almeida - Chairman, President & CEO
José E. Almeida - Chairman, President & CEO
We are -- what we have done is transformed the U.S. sales and marketing organization. We have done a very good job in selling pumps and placing pumps last year was a crescendo. This is not something that you start and get done in one quarter. The fourth quarter was the result of months and months of preparation of accounts, of bids that we won. This was not an easy, easy path. So I would say that the pumps, the way they work, they performed in the fourth quarter, they did very well. We are going down the same path and trying to get the same business in 2020. Because we think we have a pump platform currently in place and, hopefully, when approved by the FDA, which we don't have a date yet, our new pump platform, we're going to be able to perform as well or even better with the new platform because we'll have a more complete set of products that we currently don't have.
我們——我們所做的是改造了美國的銷售與行銷組織。我們在銷售幫浦與布建幫浦方面做得非常好,去年達到高峰。這不是你在一個季度就能開始並完成的事情。第四季是數月又數月的準備成果:客戶帳戶的準備、我們贏得的投標案。這並不是一條容易的路。所以我會說,幫浦——就其運作方式而言——在第四季的表現非常好。我們會沿著同樣的路徑前進,並嘗試在2020年拿到同樣的業務。因為我們認為目前已經有一個幫浦平台在位,而且——希望在獲得FDA核准之後(我們目前還沒有日期)——我們的新幫浦平台將能表現得一樣好甚至更好,因為新平台會提供更完整的產品組合,而這些是我們目前所欠缺的。
We also had good fluid sales. Remember, little anticipation of fourth quarter, not much but some anticipation of the flu season, at that time, it was not known to the world that the coronavirus was this dangerous. So I will say that this business has tremendous resilience and aided by a new platform and a good, good solid pump, which is our version 9 of our, SIGMA SPECTRUM on the market today, we feel comfortable with the trajectory going forward. Is that going to be easy? No, it's not going to be easy. But I think with the contracts that we have signed, which are more long-term contracts, and with the pumps and sets that we have, I think we can continue to aim to perform well.
我們的輸液產品銷售也表現良好。請記得,當時對第四季的預期不多,對流感季也只有一些預期;那時全世界還不知道冠狀病毒會如此危險。因此我會說,這項業務具備極強的韌性,並且在新平台以及一款非常、非常穩健的幫浦的助力下——也就是我們目前市面上的第9代 SIGMA SPECTRUM——我們對未來的發展軌跡感到放心。這會很容易嗎?不,不會容易。但我認為,憑藉我們已簽署的合約(多為較長期合約),以及我們現有的幫浦與耗材組件,我認為我們可以持續以良好表現為目標。
James K. Saccaro - Executive VP & CFO
James K. Saccaro - Executive VP & CFO
Yes. And Danielle, just to add to that, what appreciated about 2019 was that there were some unique set of circumstances that allowed us to guide to 6% growth. And part of that had to do with an easy comp and some challenges in the prior year, and then there were some other factors in play. So we were so thrilled, you can imagine, when we actually exceeded the 6% and delivered 7% growth on a full year basis, and it's really a testament to the teamwork that Joe described earlier. Having said all of that, we don't -- we've always said that 2019 was a bit of an anomaly and we will see a lowering of the growth rate a little bit more in line with what the long-term expectations are for this business. But by no means are we not incredibly excited because we are. But again, we have to appreciate the specific and unique circumstances that allow that 7% growth to occur in 2019.
是的。Danielle,我再補充一下,2019年之所以令人欣慰,是因為有一些獨特的情況,讓我們能夠指引6%的成長。其中一部分與較容易的比較基期以及前一年面臨的一些挑戰有關,另外也還有其他因素在起作用。所以你可以想像,當我們實際不僅達到6%,而是全年超越並交出7%的成長時,我們有多麼振奮;這也確實證明了Joe先前提到的團隊合作。話雖如此,我們不——我們一直都說2019年有點像是異常值,未來成長率會略為下調,更貼近這項業務的長期預期。但這絕不代表我們不感到非常興奮,因為我們確實很興奮。只是同樣地,我們必須理解並重視2019年促成7%成長的那些特定且獨特的情況。
Danielle Joy Antalffy - MD of Medical Supplies & Devices and Senior Analyst
Danielle Joy Antalffy - MD of Medical Supplies & Devices and Senior Analyst
Okay. And then I just have one quick follow-up as it relates to the generic injectables business. And how dependent is the growth on that business on upcoming new product launches? I ask the question just because it feels like there's potential for things to even slow down at the FDA. And I'm just curious as to whether the growth in that business is highly dependent upon products to come. Or do you feel like you have the portfolio right now to sustain growth there, which has been very strong.
好的。接著我還有一個關於學名注射劑業務的簡短追問。該業務的成長在多大程度上依賴即將到來的新產品上市?我之所以這麼問,是因為感覺FDA那邊可能也有進一步放慢的可能。我只是想了解,該業務的成長是否高度依賴未來要推出的產品。或者你們是否認為,以目前的產品組合就能在那裡維持成長,而那邊一直以來表現都很強勁。
José E. Almeida - Chairman, President & CEO
José E. Almeida - Chairman, President & CEO
So just a curious comment on the FDA, I expect the FDA will slow down the approval process because people are not working there, mostly working remotely. But interesting, we just got the other day, our PrisMax 2 approval just came in and came in a couple of months ahead of time. So we made some changes in hardware, improved and some software change that enable an upcoming digital portfolio with a WiFi capability and other things, the true view analytics that is going to be on the machine, so we filed for the 510(k), got approval. So we were kind of surprised, it came so fast. Perhaps that was already in the pipeline and got accelerated. But I think we -- I just got news the other day, we just filed for another molecule ahead of time with the FDA. So we can't control and speak on behalf of the FDA. The only thing I can say is that we expect and we should plan for those delays. And we'll keep you posted as we see things, as we're going to know much more, probably in a month from now when we're talking to you, about April, what is going to happen with all this -- with the environment, with the landscape of hospital purchasing patterns as well as agents approvals and things like that. But just a curious fact about one file that was sent in ahead of time, and the other one was approved way ahead of time. So some -- it's tough to predict what's coming.
關於FDA我補充一點看法:我預期FDA的核准流程會放慢,因為那裡的人多數不在辦公室工作,而是遠端作業。但有趣的是,我們前幾天剛收到PrisMax 2的核准,而且比預期提早了幾個月。所以我們在硬體上做了一些改動與改善,也做了一些軟體變更,使其能支援即將推出、具備WiFi功能等特性的數位化產品組合;機器上也會有true view analytics,因此我們提交了510(k),並獲得核准。所以我們有點驚訝,速度這麼快。也許那本來就已在流程中,並且被加速處理。但我想我們——我前幾天也剛收到消息,我們又提前向FDA提交了另一個分子(申請)。所以我們無法控制FDA,也無法代表FDA發言。我唯一能說的是,我們預期並且也應該為這些延遲做好規劃。隨著我們看到情況發展,我們會持續向各位更新;等到大概一個月後、我們再與各位對話(約在四月)時,我們應該會更清楚這一切——在這個環境下、醫院採購模式的版圖,以及藥劑核准等事項——會如何發展。但就一個有趣的事實而言:有一件是提前送件,另一件則是遠早於預期就獲得核准。所以——很難預測接下來會發生什麼。
Operator
Operator
Larry Keusch with Raymond James.
Raymond James的Larry Keusch。
Lawrence Soren Keusch - MD
Lawrence Soren Keusch - MD
Jay, you in your prepared comments, I believe, talked about the cash situation of the company, the drawdown on the European revolver, comments around the U.S. revolver. Could you talk a little bit about how you are thinking about capital allocation priorities as we think about what the stock has done, what asset valuations may be doing out there in the market? So just give us some thoughts around that as you raised, obviously, quite a bit of cash to be ready.
Jay,你在事先準備的發言中,我記得你談到了公司的現金狀況、歐洲循環信貸的動用,以及對美國循環信貸的一些評論。能否談談在考量股價表現、以及市場上資產估值可能變化的情況下,你們如何思考資本配置的優先順序?也就是說,既然你們顯然籌集了相當多的現金以備不時之需,請分享一下你們在這方面的想法。
James K. Saccaro - Executive VP & CFO
James K. Saccaro - Executive VP & CFO
Yes. Thanks, Larry. We have to be prepared for whatever we can anticipate the coronavirus will -- how that will emerge. And so as a result of that, we've been really thoughtful about having adequate capital on hand. This is the time to have the balance sheet work on our behalf, and we want to be absolutely ready to support the company. And so what we did in the first quarter is we have $200 million plus in borrowings on our European revolver, and that's a facility we use from time to time. But we've chosen to leave that $200 million -- we have cash to offset the borrowing and we have nearly $3 billion in cash. We also recently successfully redid our U.S. revolver, which has a $200 million same-day withdraw feature on it, and some other contemporary provisions that make it a best-in-class facility. And so we have all of that in place.
好的。謝謝你,Larry。我們必須為我們所能預期的各種情況做好準備——也就是冠狀病毒將如何發展、如何演變。因此,我們一直非常審慎地確保手上有充足資本。現在正是讓資產負債表為我們所用的時候,我們希望能完全做好準備來支持公司。所以我們在第一季所做的是:我們在歐洲循環信貸上借入了2億美元以上,這是一項我們不時會使用的融資工具。但我們選擇保留這2億美元——我們有現金可抵銷這筆借款,而且我們接近30億美元的現金。我們最近也成功重新安排了美國循環信貸,其中包含2億美元的同日提款功能,以及其他一些符合當代需求的條款,使其成為同級最佳的融資安排。因此,這些我們都已經就位。
What we wanted to ensure is that there would be no disruptions to our operations. So our primary objective is to ensure we have adequate liquidity on hand, despite the fact that we have a resilient and durable portfolio. We just -- we want to be ready for all circumstances that might emerge. But then, there are opportunities that could emerge as a result of this. And so we are seeing asset prices come down quite substantially in MedTech. And we've seen the share price of that should come down quite a lot. So as we think about allocation of capital and capital deployment and we also want to be ready to take advantage of those kinds of opportunities, we were pleased to close the transaction in the quarter. The Seprafilm film deal was a great one, but we do expect perhaps some of the patients that we've had over the last several years with respect to capital deployment. Let's see how that fares us in the current market environment because, as I said, we are seeing asset prices moderate down quite a bit relative to prior levels.
我們想確保的是,我們的營運不會受到任何干擾。因此我們的首要目標是確保手上有充足的流動性,儘管我們的產品組合具備韌性且耐久。我們只是——我們希望對所有可能出現的情況都做好準備。不過,這也可能帶來一些機會。因此我們看到醫療科技(MedTech)領域的資產價格大幅下滑。我們也看到相關的股價下跌了不少。所以當我們思考資本配置與資本運用時,我們也希望能準備好把握這類機會;我們很高興在本季完成了那筆交易。Seprafilm薄膜的交易非常不錯,但我們也預期,過去幾年在資本部署方面所展現的一些耐心,將在目前的市場環境中接受考驗;因為如我所說,我們正看到資產價格相較於先前水準明顯回落。
Joe, do you want to add anything to that?
Joe,你想對此補充什麼嗎?
José E. Almeida - Chairman, President & CEO
José E. Almeida - Chairman, President & CEO
Yes. First of all, our first responsibility is to ensure that we have liquidity in the company and we have plenty of that as -- and we are prepared for anything to come our way. But also, I think, it's worth noting that we kind of took a long, long pause on speaking about large acquisitions or midsized acquisitions. We could not justify prices. The P/Es were so high. And I think sometimes time is on the side of the patient, individual. And we are patient here. And I think perhaps having a good amount of money in the bank and asset values are being down, I think, maybe is an opportunity for us to continue to look at the M&A landscape, but I don't discount the fact that also our stock is -- the pricing is pretty attractive.
是的。首先,我們的首要責任是確保公司具備流動性,而我們的流動性非常充足——並且我們已為任何可能發生的情況做好準備。但同時,我認為值得注意的是,我們在談論大型或中型收購方面,某種程度上停頓了很長一段時間。我們無法為那些價格找到合理性。本益比太高了。我想有時候,時間會站在有耐心的個人這一邊。而我們在這裡是有耐心的。我也認為,或許在銀行裡有相當多的現金、且資產價值下滑之際,可能是我們持續觀察併購(M&A)版圖的一個機會;但我也不否認,我們的股票——其定價相當具有吸引力。
Operator
Operator
Our last question comes from Vijay Kumar with Evercore.
我們最後一個問題來自 Evercore 的 Vijay Kumar。
Vijay Muniyappa Kumar - MD
Vijay Muniyappa Kumar - MD
Quick, maybe a guidance question, Jay. Margins for Q1, I think I heard you say a slight expansion, maybe. Is this some incremental investments going on for Q1? And free cash conversion, looking at the restated numbers, it's in the 80s. Is that the new norm? Or should we expect that free cash conversion to step back to 90s?
Jay,快速問一個指引方面的問題。第一季的毛利率,我想我聽到你說可能會小幅擴張。這是否代表第一季會有一些額外投資?另外,自由現金轉換率,從重述後的數字來看是在 80% 多。這會是新的常態嗎?還是我們應該預期自由現金轉換率會回到 90% 多?
James K. Saccaro - Executive VP & CFO
James K. Saccaro - Executive VP & CFO
So Vijay, there is some impact in terms of investment in the first quarter related to supply chain and other activities. But this is a very fluid situation, and we're watching it very carefully. And like I say, while we are incredibly rigorous on spending across a number of areas, we have to spend to support getting supply to our patients that need it and our customers that need it, and so we will continue to do that. So this is -- stay tuned on this. We'll have some more commentary when we report Q1 results.
Vijay,第一季確實會有一些投資面的影響,與供應鏈及其他活動相關。但這是一個非常動態的情況,我們正非常密切地觀察。如我所說,雖然我們在多個領域的支出控管極為嚴謹,但為了支持把供應穩定送到有需要的病患與有需要的客戶,我們必須投入支出,因此我們會持續這麼做。所以這件事——請持續關注。在我們公布第一季結果時,會有更多評論。
As it relates to free cash flow conversion, if you look at our 2019 result, it was off our expectations. And really, there were a few factors in play. One is, we had a higher receivables balance, and there were 2 drivers of that. One is a different business mix than we expected, so we had a little bit more ex U.S. sales, in sales and higher DSO geographies, leading to a higher DSO. And then second, we had an incredibly strong December. And the result of that is those sales were not paid off with account receivable collections. Those account receivable collections occur in 2020. In addition to that, while we saw improvements in days inventory on hand, we were off a little bit our expectations. Our days payable, we did not make enough progress in this particular area. And finally, there were some higher cash tax payments than we originally budgeted for. Those are the drivers that led to our 2019 free cash flow performance. What I can tell you is our organization is incredibly focused on enhancing cash flow performance.
至於自由現金流轉換率,如果你看我們 2019 年的結果,確實低於我們的預期。主要是有幾個因素同時作用。第一,我們的應收帳款餘額較高,而這背後有兩個驅動因素。其一是業務組合與我們預期不同,因此非美國(ex U.S.)銷售占比略高,而這些地區的 DSO 較高,導致整體 DSO 上升。其二是我們 12 月表現非常強勁。其結果是,這些銷售尚未透過應收帳款回收而收款。這些應收帳款回收會在 2020 年發生。此外,雖然我們看到存貨在手天數(days inventory on hand)有所改善,但仍略低於我們的預期。而在應付帳款天數(days payable)方面,我們在這個領域的進展不夠。最後,現金稅款支付也高於我們原先編列的預算。以上這些驅動因素導致了我們 2019 年自由現金流的表現。我可以告訴你的是,我們的組織正高度聚焦於提升現金流表現。
And the number that you cited is not the new normal. We brought in a new Chief Procurement Officer, who is looking across the entire vendor base and restructuring terms and days payable terms across the vendor base. Our supply chain forecasting process started to pay dividends at the end of last year. And as we move to this year, it will pay significant dividends. So we are very optimistic about improvements in free cash flow performance and working capital balance performance, but I do have to take you back to my comments earlier on, which is over the next several months, we are not focused on that so much as we are supplying consistently our patients. And if that requires incremental inventory, which it will, we will carry incremental inventory. So we will have this factor that comes into play over the next couple of quarters. But it's going to match the tremendous progress that we're going to make across the board on free cash flow performance.
你提到的那個數字並不是新的常態。我們新聘了一位首席採購長(Chief Procurement Officer),他正在檢視整個供應商基礎,並在供應商端全面重整條款與應付帳款天數條款。我們的供應鏈需求預測流程在去年年底開始帶來成效。而隨著我們進入今年,它將帶來顯著成效。因此,我們對自由現金流表現與營運資金餘額表現的改善非常樂觀;但我也必須回到我先前的評論,也就是在接下來幾個月,我們的重點不會那麼放在這些指標上,而是放在持續、穩定地供應我們的病患。如果這需要額外的存貨——而確實會需要——我們就會持有額外存貨。因此,未來幾個季度會有這個因素介入。但它將與我們在自由現金流表現上全面取得的巨大進展相互匹配。
So with that, I think we can conclude the call. But Vijay, thanks very much for the question, we appreciate it and the support.
那麼,我想我們可以結束這通電話會議了。不過 Vijay,非常感謝你的提問,我們很感激,也感謝各位的支持。
José E. Almeida - Chairman, President & CEO
José E. Almeida - Chairman, President & CEO
Thank you all and be safe. Be protective of your health, and we wish you all well. Thank you.
謝謝大家,請注意安全。請保護好自己的健康,我們祝大家一切順利。謝謝。
Operator
Operator
Ladies and gentlemen, this concludes today's conference call with Baxter International. Thank you for participating. You may now disconnect. Everyone, have a great day.
各位女士、先生,今天 Baxter International 的電話會議到此結束。感謝各位參與。您現在可以掛線。各位,祝您有美好的一天。